Worldwide Clinical Trials Recognized as Highest Rated Phase I Provider for Overall User Preference in 2024 Industry Standard Research Phase I Benchmarking Report
Primary market research from key clinical development decision makers corroborates CRO’s industry leadership achievements and data
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–#CRO—Worldwide Clinical Trials (Worldwide), a global full-service contract research organization (CRO), proudly announces results of the 2024 Industry Standard Research (ISR) Phase I CRO Benchmarking Report. The findings confirm the importance of CRO partnerships and reinforce Worldwide’s status as a top-performing CRO for Phase I services. View the full report here.
In an industry characterized by market consolidation, other recent surveys highlight increasing concerns among pharmaceutical and biotech firms regarding the stability of large CROs. This environment underscores the need for reliable CRO partners who can deliver foundational Phase I research with consistent high quality. The ISR report not only validates Worldwide’s proven track record as a strong CRO partner but also underscores its steadfast dedication to operational excellence and leadership in an environment in which Phase I clinical trials are increasingly complex with elevated sponsor expectations and timelines.
The ISR Phase I CRO Benchmarking Report is the output of a web-based, quantitative survey of key clinical development outsourcing decision makers from small, midsize, and large biopharma companies, conducted in the fourth quarter of 2023. Worldwide was recognized as a leader with the following key metrics:
- User Preference. Worldwide ranks the highest Phase I service provider among users asked, “Which Service provider would you prefer to work with for Phase I services if the decision were completely up to you?”
- Leadership. Worldwide’s leadership scores for Phase I services outperform all other midsize CROs.
- Staff Characteristics. Worldwide is the highest rated Phase I CRO for therapeutic expertise and holds a joint first position for timely project communications.
- Services. Worldwide ranks No. 2 among the Top 3 CROs for Phase I core services – outperforming all other Phase I providers for biostatistics and data management.
- Real-Time Data Access. Worldwide ties for second position in its use of technology for real-time data access.
“These benchmark metrics are a clear indication of our commitment to continuous improvement and operational excellence at our Bioanalytical Lab and Clinical Pharmacology Unit,” said Mike Mencer, Executive Vice President and General Manager, Early Phase at Worldwide. “Phase I studies require comprehensive support to ensure both subject safety and scientific integrity. From our medical and scientific consultation and regulatory services to clinical oversight, data management, and pharmacokinetics, it’s gratifying to have further evidence that sponsors value our partnership, leadership, therapeutic expertise, and operational acumen.”
“As a sponsor, my experience working with Worldwide Clinical Trials is consistent with their results in the 2024 ISR Phase I CRO Benchmarking Report,” said Olga Ohayon, Senior Director, Clinical Operations, Rhythm Pharmaceuticals. “Through its full suite of Phase I service offerings, and its technical and therapeutic expertise, Worldwide is a truly valuable CRO partner that is able to flex to our needs and meet our timelines. It’s easy to see why they scored so high in ISR categories like ‘User Preference,’ ‘Leadership,’ and ‘Services.’”
“Sponsors tell me all the time that they like working with Worldwide because we’re as passionate about their study as they are. They want a true partner in their studies, and they feel Worldwide is an extension of their team,” said Worldwide’s CEO Peter Benton. “With the increasing complexity of Phase I trials, we understand the importance of real partnerships. We look forward to continuing to build successful relationships and helping sponsors of all sizes through their Phase I research.”
For its ISR rankings, Worldwide was recently recognized for excellence in nine categories in the 2024 CRO Leadership Awards, presented by Clinical Leader, marking the 11th consecutive year the CRO has been rated as a top-performer. Based on customer feedback, the recognition consistently highlights the company’s unwavering commitment to delivering high-quality results and unparalleled customer satisfaction in a shifting industry landscape. For details on Worldwide’s awards, click here.
For an overview of Worldwide’s Phase I service offerings, including its full suite of clinical pharmacology studies, click here.
About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.
Contacts
Media Contact:
Jill Mastrangelo
[email protected]